Frankfurt
01.04.25
08:05 Uhr
0,138 Euro
-0,004
-2,95 %
-2,95 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,086 | 0,149 | 21:47 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09:30 | Mauna Kea Technologies Announces Entrance Into Exclusive Negotiations for a Licensing Agreement for Cellvizio in an Important Therapeutic Area With a Major Industry Player | 205 | Business Wire | The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard proceedings enables Mauna Kea Technologies to intensify... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| Mo | Mauna Kea Technologies Announces the Opening of a Safeguard Proceeding to Restructure Its Financial Liabilities | 265 | Business Wire | The aim of the procedure is to optimize the Company's financial structure in order to adapt it to the needs of its future growth The procedure will also provide a protective framework favorable... ► Artikel lesen | |
| 06.03. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 215 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.03. | Mauna Kea Technologies: Cellvizio Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis | 218 | Business Wire | ESGE, Europe's leading endoscopy society, endorses Cellvizio® as a key tool for improving pancreatic cyst diagnostic accuracy, marking a major step towards broader commercial adoption
Regulatory... ► Artikel lesen | |
| 06.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 235 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 27.01. | Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio for Precision Surgery in Head and Neck Cancers | 309 | Business Wire | Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx, oropharynx and hypopharynx Cellvizio helped identify... ► Artikel lesen | |
| 21.01. | Mauna Kea Technologies: Half-Year Liquidity Contract Statement for H2 2024 With the Brokerage Firm Gilbert Dupont | 626 | Business Wire | Regulatory News:
Under the liquidity contract between the company MAUNA KEA TECHNOLOGIES (Paris:ALMKT) and the brokerage firm Gilbert Dupont, the following resources appeared on the liquidity account... ► Artikel lesen | |
| 20.01. | Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex | 316 | Business Wire | 13th U.S. AI patent awarded to Mauna Kea Expanded patent portfolio boosts platform value, supports strategic partnerships
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT)... ► Artikel lesen | |
| 15.01. | Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update | 375 | Business Wire | Full Year Sales excluding licenses of €5.6m, down 9% YoY amid delayed capital sales and no revenue from JV in China Two specialized investment banks RM Global and Bucephale Finance mandated to... ► Artikel lesen | |
| 14.01. | Mauna Kea Technologies Announces Its 2025 Financial Calendar | 245 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®,the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces... ► Artikel lesen | |
| 09.01. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 393 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.12.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 353 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 26.11.24 | Mauna Kea Technologies: Raising Pancreatic Cancer Awareness Through Patient Voices | 161 | Business Wire | With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic Cancer
Regulatory News:
This Pancreatic Cancer Awareness Month... ► Artikel lesen | |
| 20.11.24 | Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador | 122 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is pleased... ► Artikel lesen | |
| 13.11.24 | Mauna Kea Technologies Provides an Update on Its Recent Developments | 345 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, provides... ► Artikel lesen | |
| 06.11.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 322 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website:... ► Artikel lesen | |
| 17.10.24 | Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance | 420 | Business Wire | Major New Study Presented at the World's Largest Gastroenterology Congress Validation of Mauna Kea's Growth Strategy with CellTolerance® in a $6 Billion a Year Market Opportunity
Regulatory... ► Artikel lesen | |
| 15.10.24 | Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales | 411 | Business Wire | Confirmation of lower breakeven point trajectory with 9% Reduction in Operational Expenses Q3 2024 Sales Growth of +24%1 Driven by New System Sales in the U.S. and Europe Official Launch of... ► Artikel lesen | |
| 04.10.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 481 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 01.10.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 288 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,102 | +4,07 % | Sernova Aktie: Positives Umsatzwachstum gemeldet! | Das Biotechnologieunternehmen erweitert sein Führungsteam, sichert Finanzierungen und erhält FDA-Freigabe für klinische Studien zur Behandlung von Hypothyreose. Sernova Biotherapeutics, ehemals Sernova... ► Artikel lesen | |
| FAMICORD | 3,880 | -2,02 % | Vita 34 firmiert um: Neuer Name FamiCord AG | Die Vita 34 AG firmiert ab sofort unter dem Namen FamiCord AG. Der neue Name basiert auf der bekanntesten Konzernmarke und soll die Expansion des Leipziger Unternehmens in weitere Geschäftsfelder unterstützen.... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,220 | -5,29 % | Geratherm Medical Aktie: Ruhige Zeiten angekündigt? | Das Medizintechnikunternehmen passt Produktionskapazitäten für klinische Thermometer bei fortgesetzter Marktschwäche an, während die Aktie trotz Volatilität zuletzt zulegte. Die Geratherm Medical AG... ► Artikel lesen | |
| PLUS THERAPEUTICS | 1,010 | +6,30 % | PLUS THERAPEUTICS, INC. - 10-K, Annual Report | ||
| ATOSSA THERAPEUTICS | 0,613 | -3,46 % | Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst | ||
| MEDICLIN | 2,980 | 0,00 % | EQS-News: MEDICLIN AG: MEDICLIN beendet erfolgreiches Geschäftsjahr 2024 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Jahresbericht/Sonstiges
MEDICLIN beendet erfolgreiches Geschäftsjahr 2024
28.03.2025 / 10:24 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Signs Sourcing Partnership With Windtree, Expects To Reduce Production Cost Of Phexxi By 60% | ||
| SONOMA PHARMACEUTICALS | 2,520 | -100,00 % | Sonoma Pharmaceuticals, Inc. - 8-K, Current Report | ||
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-Q, Quarterly Report | ||
| VERU | 0,605 | +33,55 % | Veru Aktie: Kreuzung ohne klare Richtung! | Die Veru-Aktie konnte im jüngsten Handel einen leichten Aufschwung verzeichnen. Am 22. März stieg der Kurs um 2,35% auf 0,48 EUR, was eine positive Entwicklung gegenüber dem Vortagsschluss darstellt.... ► Artikel lesen | |
| LIFEWARD | 1,730 | +1,47 % | Lifeward Ltd.: FDA Issues Clearance for ReWalk 7 Exoskeleton | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| LIGHT AI | 0,370 | -3,65 % | Light AI Appoints Renowned Silicon Valley Leader, Anthony Schaller, as President & Chief Technology Officer and Announces Consumer Product Commercialization in Q3 2025 | ||
| EKSO BIONICS | 0,395 | +2,33 % | Ekso Bionics Holdings Aktie: Beeindruckende Innovationskraft | Der Exoskelett-Hersteller verzeichnet im letzten Quartal 2024 Umsatzsteigerungen und Margenwachstum, kämpft jedoch mit Jahresrückgang bei hoher Aktienvolatilität. Ekso Bionics meldete für das vierte... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 50,12 | +1,03 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen zum zweiten Quartal auf "Buy" mit einem Kursziel von 65 Euro belassen. Die Geschäfte in... ► Artikel lesen | |
| FRESENIUS | 39,480 | +0,28 % | UBS stuft Fresenius SE auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Fresenius von 40 auf 47 Euro angehoben und die Einstufung auf "Buy" belassen. Der Fokus der Bad Homburger liege inzwischen... ► Artikel lesen |
Das Unternehmen MAUNA KEA TECHNOLOGIES kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,95 % bei einem Aktienkurs von 0,138 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.
